Jefferies Resumes Coverage on Sequenom (SQNM) at Hold, Price Target $7
Tweet
Share
E-mailGet Alerts SQNM Hot Sheet
Price: $2.39 --0%
Rating Summary:
3 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
3 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Jefferies is resuming coverage on shares of Sequenom (NASDAQ: SQNM) with a Hold rating and $7 price target, as they believe that Dr. Dennis Lo's independent data and SQNM's "Locked Assay" study, has ultimately confirmed that multiplexed maternal plasma DNA sequencing analysis can be used to rule out fetal T21 among high risk pregnancies.
The firm reports that while the test might be faster, its aggregate no call rate of ~7% is higher than the acceptable rate of ~5% for commercially available complex diagnostic tests.
Jefferies comments that they predict legal matters arising later on with Dr. Dennis Lo who is affiliated with SQNM and Dr. Steven Quake who is affiliated with Artemis, Fluidigm, they are both the key researchers behind pending and issued patents relating to the detection of chromosomal aneuploidies using sequencing and dPCR.
For more ratings news on Sequenom click here and for the rating history of Sequenom click here.
Shares of Sequenom closed at $5.56 yesterday.
The firm reports that while the test might be faster, its aggregate no call rate of ~7% is higher than the acceptable rate of ~5% for commercially available complex diagnostic tests.
Jefferies comments that they predict legal matters arising later on with Dr. Dennis Lo who is affiliated with SQNM and Dr. Steven Quake who is affiliated with Artemis, Fluidigm, they are both the key researchers behind pending and issued patents relating to the detection of chromosomal aneuploidies using sequencing and dPCR.
For more ratings news on Sequenom click here and for the rating history of Sequenom click here.
Shares of Sequenom closed at $5.56 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DA Davidson Starts Everus (ECG) at Buy
- TD Cowen Assumes Maze Therapeutics (MAZE) at Buy
- TD Cowen Assumes Atara Biotherapeutics (ATRA) at Buy
Create E-mail Alert Related Categories
New CoverageRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
